EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical validation and utility of targeted nanopore sequencing for rapid pathogen diagnosis and precision therapy in lung cancer patients with pulmonary infections

Qingmei Deng, Yanzhe Liu, Jian Zhang, Hongshan Zhang, Yiyong Zhang, Meng Wang, Min Jia, Dushan Ding, Yuqin Fang, Yunfei Wang, Hongcang Gu, Hongzhi Wang

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2025.1730098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Qingmei Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Science Island Branch of Graduate School, University of Science and Technology of China, Hefei, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Nanopore Sequencing, Respiratory Tract Infections, Precision Medicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary infections are common in patients with lung cancer (LC), complicating diagnosis and treatment. This study explored the diagnostic performance and clinical utility of targeted nanopore sequencing (TNPseq) for detecting pathogens in LC-related pulmonary infections.

Methods

A total of 143 patients with LC or benign pulmonary diseases complicated by pulmonary infections were included and stratified into diagnostic and therapeutic cohorts. Sputum samples underwent conventional culture, metagenomic next-generation sequencing (mNGS), and TNPseq analyses. Microbiota profiles were compared across disease groups and correlated with tumor therapy responses. In the therapeutic cohort, clinical outcomes were assessed between empirical therapy and TNPseq-guided therapy.

Results

TNPseq identified a significantly higher proportion of clinically relevant pathogens compared to mNGS (48.76% vs. 16.80%, p < 0.001) and demonstrated superior sensitivity (81.25% vs. 68.75%), with a 40.7% reduction in turnaround time (16 hours vs. 27 hours). Both sequencing methods revealed an enrichment of Lactobacillus species in non-initial diagnosis lung cancer (NDLC) patients (p < 0.01). Patients exhibiting partial response or stable disease (PR/SD) showed increased abundance of Neisseria , Veillonella , and Prevotella species (p < 0.05). Clinical remission was achieved in all patients; however, 68.4% of those initially receiving empirical therapy subsequently required a switch to TNPseq-guided treatment due to its ineffectiveness. Compared to this empirical-to-TNPseq group, the median treatment duration was significantly shorter under direct TNPseq guidance (total: 6 days vs. 13 days, p < 0.01; LC subgroup: 5 days vs. 15.5 days, p < 0.05), thereby reducing unnecessary antibiotic exposure.

Conclusions

By enabling rapid pathogen detection and profiling of the pulmonary microbiome, TNPseq facilitates targeted therapy and reduces antibiotic overuse in LC patients. These findings highlight the potential of TNPseq as a promising, rapid, and non-invasive diagnostic candidate for first-line use, offering a comprehensive view of both infection and host-microbe interactions in immunocompromised patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsNanopore SequencingRespiratory Tract InfectionsPrecision MedicineHumansFemaleAgedMaleSputumMiddle AgedHigh-Throughput Nucleotide SequencingMicrobiotaMetagenomicsSensitivity and SpecificityBacteriaAged, 80 and over

Stichwörter der Autor:innen

lung cancerprecision therapypulmonary infectionsrapid pathogen diagnosistargeted nanopore sequencing

Autor:innen und Institutionen

  • Science Island Branch of Graduate School, University of Science and Technology of China, Hefei, China.
  • Hefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China.
  • Hefei CAS-Hongshuo Medical Laboratory Ltd, Hefei, China.
  • Hangzhou Shengting Medical Technology Co., Ltd, Hangzhou, China.
  • Institute of Health Education, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.
  • Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, China.

Zitieren

APA

Deng, Q., Liu, Y., Zhang, J., Zhang, H., Zhang, Y., Wang, M., Jia, M., Ding, D., Fang, Y., Wang, Y., Gu, H., & Wang, H. (2026). Clinical validation and utility of targeted nanopore sequencing for rapid pathogen diagnosis and precision therapy in lung cancer patients with pulmonary infections. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1730098

Vancouver

Deng Q, Liu Y, Zhang J, Zhang H, Zhang Y, Wang M, et al. Clinical validation and utility of targeted nanopore sequencing for rapid pathogen diagnosis and precision therapy in lung cancer patients with pulmonary infections. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2025.1730098

BibTeX
@article{Deng2026,
  author = {Deng, Qingmei and Liu, Yanzhe and Zhang, Jian and Zhang, Hongshan and Zhang, Yiyong and Wang, Meng and Jia, Min and Ding, Dushan and Fang, Yuqin and Wang, Yunfei and Gu, Hongcang and Wang, Hongzhi},
  title = {Clinical validation and utility of targeted nanopore sequencing for rapid pathogen diagnosis and precision therapy in lung cancer patients with pulmonary infections},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2025.1730098}
}
Kostenlos starten →